REFERENCES
  1. Kaplan AP, Joseph K. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade.Immunol Allergy Clin N Am. 2017;37(3):513-25.
  2. Zuraw BL, Christiansen SC. HAE: pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016; 51(2): 216-29.
  3. Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med.2020;382:1136-48.
  4. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.Allergy Ast Proc. 2010;31(5):407-14.
  5. Lumry WR, Settipane RA. Hereditary angioedema: Epidemiology and burden of disease.Allergy Asthma Proc. 2020;1;41(Suppl 1):S08-S13.
  6. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130:692-97.
  7. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci. 1888;95:362–367.
  8. Leibovich-Nassi I, Reshef A. The Enigma of Prodromes in Hereditary Angioedema (HAE). Clin Rev Allergy Immunol. 2021; 61(1):15-28.
  9. Kemp JG, Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review.Allergy Ast Proc. 2009;30:493-499.
  10. Prematta MJ, Kemp JG, Gibbs JG, Craig TJ. Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks.Allergy Ast Proc. 2009;30:506-511.
  11. Prematta MJ, Bewtra AK, Levy RJ, Wasserman RL, Jacobson KW, Machnig T, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther. 2012;29(10):913-922.
  12. Reshef A, Prematta M, Craig TJ. Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. Allergy Ast Proc. 2013;34(3):261-266.
  13. Leibovich-Nassi I, Golander H, Somech R, Har-Even D, Reshef A. New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA). Clin Rev Allergy Immunol.2021;61(1):29-39.
  14. Kaplan AP, Joseph K. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade.Immunol Allergy Clin N Am. 2017;37(3):513-525.
  15. Hofman ZLM, Relan A, Zeerleder S, Drouet C, Zuraw B, Hack CE. Angioedema attacks in patients with hereditary angioedema: local manifestations of a systemic activation process. J Allergy Clin Immunol. 2016; 138:359-366.
  16. Magerl M, Bader M, Gompel A, Joseph K, Kaplan AP, Kojda G et al. Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012. Inflamm Res. 2014; 63:173-178.
  17. Luyasu S, Charignon D, Ponard D, Drouet C, Ghannam A. Angioedema: Systemic activation process during prodromes. Ann Allergy Ast Immunol. 2018;121(2):248-249.
  18. Santana MJ, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res. 2014;23:1505-13.
  19. Nelson EC, Eftimovska E, Lind C et al, Patient Reported outcome measures in practice. Brit Med J. 2015; 350: g7818.
  20. Leibovich-Nassi I, Reshef A, Somech R, Golander H. A survey of hereditary angioedema in Israel. Allergy, Ast Clin Immunol. 2017;13 (Suppl 2): 34
  21. Barlow JH, Cullen A, Rowe IF. Comparison of knowledge and psychological well-being between patients with a short disease duration and patients with more established rheumatoid arthritis.Pat Edu Counsel. 1999; 38:195-203.
  22. Scully JL. What is a disease? Disease, disability and their definitions. Europ Moll Biology Organ Rep. 2004;5(7):650-653.
  23. Lazarus R, Folkman S. Stress, Appraisal and Coping. New York, Springer; 1984.
  24. Maurer M, Aberer W, Bouillet L et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.PLoS One. 2013;8(2):e53773.
  25. Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44(9): 865-872.
  26. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26:1209-1213
  27. Houtveen JH, Sorbi MJ. Prodromal functioning of migraine patients relative to their interictal state - An ecological momentary assessment study. PLoS One. 2013;8(8).
  28. Lidar M, Yaqubov M, Zaks N et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever.J Rheumatol. 2006;33(6):1089-1092.
  29. Babaoglu H, Varan O, Kucuk H et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF).Clin Rheumatol. 2019; 38(2):577-581.
  30. Kreiberg KB, Bygum A. Reporting through smartphone application results in detailed data on acquired and hereditary angioedema attacks.Allergy. 2019; 74:1800-1802.
  31. Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema- the 2017 revision and update. Allergy.2018;73:1575-96.
  32. Betschel S, Badiou J, Binkley K et al. The International/ Canadian Hereditary Angioedema Guideline. Allergy Ast Clin Immunol. 2019; 15:72.
  33. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021; 9(1):132-150.e3.
Legends/captions to Tables